XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
Affected assets and topics
Why it matters
XORTX Therapeutics Inc. has issued a correction notice for a previously released press statement on April 17, 2025, and announced a 180-day extension to regain compliance with Nasdaq's minimum bid price deficiency. The company's shares are listed on the NASDAQ, TSXV, and Frankfurt exchanges.
Article tone
Expected market reaction
The correction notice and extension announcement may lead to short-term market volatility, but the overall impact on the company's stock price is likely to be minimal. The extension provides XORTX with additional time to address the bid price deficiency, which may alleviate some concerns among investors.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 80
Original source
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that a press release that had previously been issued on April 17, 2025 was re-issued in error today. Please disregard this prior press release. XORTX announces that it received today a notice (the “Extension
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on October 21, 2025. Analysis and insights provided by AnalystMarkets AI.